Skip to Main content Skip to Navigation
Master Thesis

Perspective d’un suivi thérapeutique pharmacologique de l’évérolimus en cancérologie ? Résultats d’une étude exploratoire de la relation concentration-effet de l’évérolimus

Abstract : In oncology, on the contrary to transplantation, the TDM of everolimus (EVR) is not mandatory and up until now, no target for trough level (C0) has been defined, even though patients receive 5 to 10 times higher doses than those used in transplantation. Fifty four patients were included in our study. Adverse event (all grades) was reported in 75.9% of the patients (EVR termination in 25.9% patients). A C0 EVR threshold of 26.3 ng/mL was associated with a 4-fold increased risk of toxicity (C0>26.3 ng/mL: HR=4.12, IC95%=[1.48- 11.5], p=0.0067) whereas a C0 EVR threshold of 11.9 ng/mL was associated with a 3-fold increased risk of progression (C0<11.9 ng/mL: HR=3.2, IC95%=[1.33-7.81],p=0.001). C0 was significantly lower in carriers of at least one CYP3A5*1 allele (intercept(expressors)=10.72±1.45 ng/mL, βnon expressors=+6.32±2.22 ng/mL, p=0.0044). No association was found between carriers of the CYP3A4*22 variant and C0. These results are in favour of TDM for EVR in oncology.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [43 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-01499884
Contributor : Bu Carreire Université de Bordeaux <>
Submitted on : Saturday, April 1, 2017 - 11:52:29 AM
Last modification on : Wednesday, August 23, 2017 - 4:41:43 PM
Long-term archiving on: : Sunday, July 2, 2017 - 12:37:10 PM

Identifiers

  • HAL Id : dumas-01499884, version 1

Collections

Citation

Marine Deppenweiler. Perspective d’un suivi thérapeutique pharmacologique de l’évérolimus en cancérologie ? Résultats d’une étude exploratoire de la relation concentration-effet de l’évérolimus. Sciences pharmaceutiques. 2017. ⟨dumas-01499884⟩

Share

Metrics

Record views

186

Files downloads

594